Drug-eluting stents

Onyx Frontier™ drug-eluting stent (DES)

<p>The Onyx Frontier™ drug-eluting stent (DES) is used in complex percutaneous coronary intervention (PCI).</p>

Ordering information
Contact a representative

Features

Enhanced delivery system†

The Onyx Frontier™ DES is engineered to deliver,† featuring:

  1. A dual-flex balloon
  2. A lower crossing profile4
  3. Increased catheter flexibility5
This image shows the deliverability enhancements for Onyx Frontier™ drug-eluting stent.

See the latest technology in action.

Deliverability comparison — 3.0 mm DES†,6

(Lower is better)

This graph compares the deliverability of Onyx Frontier™ drug-eluting stent with competitive stents.

2-D track maximum force (GF scaled)

Onyx Frontier™ is the most deliverable DES yet.†,6

  • 16% more deliverable than Resolute Onyx™ DES
  • 24% more deliverable than Orsiro™* Mission DES
  • 46% more deliverable than SYNERGY™* XD DES
  • 62% more deliverable than XIENCE Skypoint™* DES

Stent crossing profile comparison — 3.0 mm DES7

(Lower is better)

This graph compares the crossing profile of Onyx Frontier™ drug-eluting stent with competitive stents.

Average stent crossing profile (in)

Onyx Frontier™ is the only 3.0 mm DES with a crossing profile less than 1 mm.7

† Stent delivery system updates were implemented on the 2.0–4.0 mm Onyx Frontier DES diameters.

 

Back to top

Product details

Onyx Frontier™ DES is different by design, featuring a single-wire design, platinum-iridium core, zotarolimus drug and BioLinx™ polymer, and a broad diameter range.

Single-wire design

Only Medtronic drug-eluting stents are made from a single wire, versus laser cutting, to enable a fluid range of motion for increased flexibility and the conformability needed for superior strut apposition.1

The Resolute Onyx™ DES sinusoid formed wire is one component in our continuous sinusoid technology.

Sinusoid formed wire

Resolute Onyx™ DES in a helical wrap formation is one component in our continuous sinusoid technology.

Helical wrap

Resolute Onyx™ DES is laser-fused.

Laser-fusion

Platinum-iridium core

The platinum-iridium core within Onyx Frontier™ DES is more visible8 than competitive DES for precise placement and follow-up treatment (while enabling greater radial strength9 with thin struts).‡

  1. Platinum-iridium core
  2. Cobalt alloy shell
This image shows the platinum-iridium core and cobalt alloy shell of Onyx Frontier™ drug-eluting stent.

Visibility comparison — 3.0 mm DES8

(Higher is better)

This graph compares the visibility of Onyx Frontier™ drug-eluting stent with competitive stents.

 

Average X-ray visibility index (%)

Zotarolimus drug and BioLinx™ polymer

The zotarolimus drug inhibits neointimal growth10 while the BioLinx™  biocompatible polymer — the only polymer specifically designed for a DES — promotes faster healing.3

This image depicts an illustration of our BioLinx™ polymer.

MRI safety

Nonclinical testing has demonstrated that the Onyx Frontier DES is MR Conditional for single and overlapping lengths up to 120 mm. A person with the Onyx Frontier DES implant may be safely scanned under the conditions found in the Onyx Frontier DES instructions for use. Failure to follow these conditions may result in injury.

Broad diameter range

Only Medtronic offers DES in 2.0 mm to 5.0 mm sizes, providing four platforms specifically designed to meet the needs of each vessel size.

Platform Stent
diameter (mm)		 Stent length (mm) MSID◊ (mm)
(post-dilatation limit)
Small
vessels		 2.00 8 12 15 18 22 26 30 — — 3.50
2.25 8 12 15 18 22 26 30 34 38 3.50
2.50 8 12 15 18 22 26 30 34 38 3.50
Medium
vessels		 2.75 8 12 15 18 22 26 30 34 38 4.00
3.00 8 12 15 18 22 26 30 34 38 4.00
Large
vessels		 3.50 8 12 15 18 22 26 30 34 38 5.00
4.00 8 12 15 18 22 26 30 34 38 5.00
Extra-large
vessels		 4.50 — 12 15 18 22 26 30 — — 6.00
5.00 — 12 15 18 22 26 30 — — 6.00

 

 

Back to top

Complex PCI

Onyx Frontier™ DES is optimized for complex PCI.

An exclusive set of design features and clinical data◊ help ensure you have a reliable DES, even for your most challenging cases, including bifurcation PCI, one-month DAPT in high bleeding risk (HBR) patients, extra-large and extra-small vessels, and chronic total occlusion (CTO).

Bifurcation PCI

As the first and only DES indicated for the treatment of non-LM bifurcation lesions using the provisional technique, Onyx Frontier™ DES helps you:

  • Treat complex bifurcation anatomy with a highly conformable stent platform11
  • Access the side branch more easily with rounded struts12
  • Open the stent cell to the side branch while maintaining consistent scaffolding13 and strength13
This image shows the Onyx Frontier™ drug-eluting stent (DES) inside the anatomy under fluoroscopy.

Onyx Frontier™ DES is optimized for bifurcation with bifurcation education built for you.

This image shows a close-up of the Onyx Frontier™ drug-eluting stent (DES) single-wire design that optimizes the main branch without compromising the side branch during bifurcation.

Unique, single-wire design provides the features necessary to optimize the main branch without compromising the side branch11

This chart shows the performance goal with low TVF event rates at one year for 24.5 percent.

ONYX PAS Bifurcation Study

Beat the performance goal◊ derived from contemporary trials with low event rates at one year◊,15

This is an image showing a healthcare professional looking at a screen showing scans of a heart at the Visible Heart Lab.

Portfolio of comprehensive bifurcation education to support your complex practice

One-month DAPT in high bleeding risk (HBR) patients

  • Onyx Frontier™ DES is indicated for HBR patients and labeled for one-month DAPT.§,16
  • Based on the results from the Onyx ONE Clear Analysis, which evaluated Resolute Onyx™ DES in the most complex HBR patients17
See all the Onyx ONE data

Complex patients

  • 74 years average age
  • ~50% ACS patients
  • 39% diabetes patients

Complex lesions

  • 50% moderate to severe calcified lesions
  • 79% B2/C lesions
  • 37 mm average stented length
  • > 60 mm stented length in 225 patients18

DAPT duration decisions are best made on an individual basis. Premature discontinuation or interruption of prescribed antiplatelet medication could result in a higher risk of ST, MI, or death.

Extra-large vessels
(4.50–⁠5.00 mm size)

Specifically designed with additional crowns and thicker struts19 (versus core sizes) to provide the radial strength needed for extra-large vessels.20

Extra-small vessels
(2.00–⁠2.50 mm size)

  • Only DES family with 2.00 mm size
  • Low crossing profile — less than 1 mm21
  • Demonstrated 2% target lesion revascularization and 0% stent thrombosis at one year in a complex, small-vessel population22
This image shows how Onyx Frontier™ drug-eluting stent expands to 6.0 mm when expanded to its maximum stent inner diameter.

Expands from 4.50  mm up to 6.00 mm while maintaining structural integrity

This image shows how Onyx Frontier™ drug-eluting stent expands to 3.5 mm when expanded to its maximum stent inner diameter.

2.00–2.50 mm expand up to 3.50 mm

Chronic total occlusion (CTO)

The demonstrated deliverability23, low crossing profile24, and visibility2 of the Onyx™ DES platform make it ideal for CTOs.

More CTO resources are available on Medtronic Academy.

 

View CTO resources (open in new window)
This image shows a physician in a cath lab reviewing an image.

 

Back to top

Ordering information

Item number Nominal expanded
stent ID (mm)		 Nominal unexpanded
stent length (mm)		 Nominal zotarolimus
content (μg)
ONYXNG20008UX 2.0 8 51
ONYXNG22508UX 2.25 8 51
ONYXNG25008UX 2.5 8 51
ONYXNG27508UX 2.75 8 67
ONYXNG30008UX 3.0 8 67
ONYXNG35008UX 3.5 8 77
ONYXNG40008UX 4.0 8 77
ONYXNG20012UX 2.0 12 70
ONYXNG22512UX 2.25 12 70
ONYXNG25012UX 2.5 12 70
ONYXNG27512UX 2.75 12 94
ONYXNG30012UX 3.0 12 94
ONYXNG35012UX 3.5 12 108
ONYXNG40012UX 4.0 12 108
ONYXNG45012UX 4.5 12 132
ONYXNG50012UX 5.0 12 132
ONYXNG20015UX 2.0 15 85
ONYXNG22515UX 2.25 15 85
ONYXNG25015UX 2.5 15 85
ONYXNG27515UX 2.75 15 117
ONYXNG30015UX 3.0 15 117
ONYXNG35015UX 3.5 15 132
ONYXNG40015UX 4.0 15 132
ONYXNG45015UX 4.5 15 158
ONYXNG50015UX 5.0 15 158
ONYXNG20018UX 2.0 18 104
ONYXNG22518UX 2.25 18 104
ONYXNG25018UX 2.5 18 104
ONYXNG27518UX 2.75 18 140
ONYXNG30018UX 3.0 18 140
ONYXNG35018UX 3.5 18 156
ONYXNG40018UX 4.0 18 156
ONYXNG45018UX 4.5 18 188
ONYXNG50018UX 5.0 18 188
ONYXNG20022UX 2.0 22 127
ONYXNG22522UX 2.25 22 127
ONYXNG25022UX 2.5 22 127
ONYXNG27522UX 2.75 22 171
ONYXNG30022UX 3.0 22 171
ONYXNG35022UX 3.5 22 186
ONYXNG40022UX 4.0 22 186
ONYXNG45022UX 4.5 22 227
ONYXNG50022UX 5.0 22 227
ONYXNG20026UX 2.0 26 146
ONYXNG22526UX 2.25 26 146
ONYXNG25026UX 2.5 26 146
ONYXNG27526UX 2.75 26 198
ONYXNG30026UX 3.0 26 198
ONYXNG35026UX 3.5 26 221
ONYXNG40026UX 4.0 26 221
ONYXNG45026UX 4.5 26 265
ONYXNG50026UX 5.0 26 265
ONYXNG20030UX 2.0 30 168
ONYXNG22530UX 2.25 30 168
ONYXNG25030UX 2.5 30 168
ONYXNG27530UX 2.75 30 225
ONYXNG30030UX 3.0 30 225
ONYXNG35030UX 3.5 30 252
ONYXNG40030UX 4.0 30 252
ONYXNG45030UX 4.5 30 304
ONYXNG50030UX 5.0 30 304
ONYXNG22534UX 2.25 34 187
ONYXNG25034UX 2.5 34 187
ONYXNG27534UX 2.75 34 257
ONYXNG30034UX 3.0 34 257
ONYXNG35034UX 3.5 34 282
ONYXNG40034UX 4.0 34 282
ONYXNG22538UX 2.25 38 206
ONYXNG25038UX 2.5 38 206
ONYXNG27538UX 2.75 38 284
ONYXNG30038UX 3.0 38 284
ONYXNG35038UX 3.5 38 317
ONYXNG40038UX 4.0 38 317

Related links

Similar products

TM* Third-party brands are trademarks of their respective owners.

† Stent delivery system updates were implemented on the 2.0–4.0 mm Onyx Frontier™ DES diameters.

‡ Onyx Frontier™ DES has the same stent platform, with platinum-iridium core, as Resolute Onyx™ DES. 

§ Clinical data evaluating Resolute Integrity™ and Resolute Onyx™ DES apply to Onyx Frontier™ DES.

◊ Clinical data evaluating Resolute Onyx™ DES applies to Onyx Frontier™ DES

¶ Stents should not be expanded to a diameter beyond the maximum labeled diameter listed per the IFU. Post-dilation required for overexpansion.

  1. Third-party modeling and analysis on file at Medtronic (Mortier Conformability Report). May not be indicative of clinical performance. Evaluated the following stent platforms: Resolute Onyx DES, SYNERGY DES, and XIENCE Alpine™* DES (Multi-Link 8™* BMS platform).
  2. Based on bench test data on file at Medtronic (University of Budapest Visibility Testing). May not be indicative of clinical performance. N = 3 of each DES tested (3.0 mm) Onyx Frontier DES, Orsiro®* DES, XIENCE Alpine DES, and SYNERGY DES.
  3. Roleder T, Kedhi E, Berta B, et al. Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study. Adv Interv Cardiol. 2019;15(2):143-150.

  1. Based on bench test data on file at Medtronic (D00339634). Compared to Resolute Onyx DES. N = 5 of each DES tested (3.0 x 18 mm).
  2. Based on bench test data on file at Medtronic (Frontier Outer Shaft Comparison Study). May not be indicative of clinical performance. Compared to Resolute Onyx catheter. N = 5 of each tested.
  3. Based on bench test data on file at Medtronic (D00339634, method D00117002). May not be indicative of clinical performance. N = 7 of each DES tested.
  4. Based on bench test data on file at Medtronic (D00339634). N = 5 of each DES tested.
  5. Based on bench test data on file at Medtronic (University of Budapest Visibility Testing). May not be indicative of clinical performance. N = 3 of each DES tested.
  6. Based on bench test data on file at Medtronic (10166182DOC). May not be indicative of clinical performance. Minimum N = 3 of each DES tested (3.0 mm) Onyx Frontier DES, Orsiro DES, XIENCE Sierra™* DES, and SYNERGY DES.
  7. Yeh RW, Silber S, Chen L, et al. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program. JACC Cardiovasc Interv. February 2017;10(3):247-254.
  8. Third-party modeling and analysis of 3.0 mm stents on file at Medtronic (Mortier Bifurcation Simulation Report). May not be indicative of clinical performance.
  9. Bench test data on file at Medtronic (Tip Catch Test Analysis) comparing stents with rounded struts versus squared struts (3.0 mm). N = 10 of each design tested. May not be indicative of clinical performance.
  10. Based on bench test data on file at Medtronic (D00821940). May not be indicative of clinical performance. N = 3 of each stent design tested.
  11. Based on modeling of medium-vessel stents on file at Medtronic (D00642693). May not be indicative of clinical performance.
  12. Price M, Boutis L, Kirtane A, et al. One Year Clinical Outcomes in Patients with Coronary Bifurcation Lesions: Results from the Resolute Onyx Bifurcation Study. J Am Coll Cardiol. May 2021;77(18_suppl_1):965.
  13. Onyx Frontier DES Instructions for Use.
  14. Kandzari DE, Kirtane AJ, Windecker S, et al. One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. Circ Cardiovasc Interv. November 2020;13:e009565.
  15. Kandzari D, et al. Complex PCI with 1-month DAPT in HBR Patients. Presented at TCT 2020.
  16. Based on stent design (10082545DOC).
  17. Based on bench test data on file at Medtronic (D00333762). May not be indicative of clinical performance. N = 5 of 5.0 x 18 mm tested.
  18. Based on bench test data on file at Medtronic (D00339634). May not be indicative of clinical performance. N = 5 of 2.0 x 18 mm tested.
  19. Cuellas C, et al. Use of a Zotarolimus-eluting stent for small vessel disease (DISCO 9 Study). Presented at PCR 2021.
  20. Based on bench test data on file at Medtronic (D00339634, method D00117002). May not be indicative of clinical performance. N = 7 of each DES tested (3.0 mm diameter): Onyx Frontier DES, Resolute Onyx DES, XIENCE Skypoint DES, and Orsiro Mission DES.
  21. Based on bench test data on file at Medtronic (D00339634). N = 5 of each DES tested (3.0 mm diameter): Onyx Frontier DES, Resolute Onyx DES, XIENCE Skypoint DES, and Orsiro Mission DES.